{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:53:20Z","timestamp":1790394800188,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006281.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000}}],"reference-count":216,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006281.pub5","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T14:34:36Z","timestamp":1576074876000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Drug treatment for spinal muscular atrophy type I"],"prefix":"10.1002","author":[{"given":"Renske I","family":"Wadman","sequence":"first","affiliation":[{"name":"University Medical Center Utrecht, Brain Center Rudolf Magnus; Department of Neurology; Heidelberglaan 100 Utrecht Netherlands 3584 CX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Ludo","family":"van der Pol","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Brain Center Rudolf Magnus; Department of Neurology; Heidelberglaan 100 Utrecht Netherlands 3584 CX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy MJ","family":"Bosboom","sequence":"additional","affiliation":[{"name":"Onze Lieve Vrouwe Gasthuis locatie West; Department of Neurology; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fay-Lynn","family":"Asselman","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Brain Center Rudolf Magnus; Department of Neurology; Heidelberglaan 100 Utrecht Netherlands 3584 CX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard H","family":"van den Berg","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Brain Center Rudolf Magnus; Department of Neurology; Heidelberglaan 100 Utrecht Netherlands 3584 CX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan T","family":"Iannaccone","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center; Department of Pediatrics; 5323 Harry Hines Boulevard Dallas Texas USA 75390"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander FJE","family":"Vrancken","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Brain Center Rudolf Magnus; Department of Neurology; Heidelberglaan 100 Utrecht Netherlands 3584 CX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,12,11]]},"reference":[{"issue":"18","key":"10.1002\/14651858.CD006281.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0002|cit2","unstructured":"NCT02193074 A study to assess the efficacy and safety of IONIS-SMN rx in infants with spinal muscular atrophy clinicaltrials.gov\/show\/NCT02193074"},{"issue":"11","key":"10.1002\/14651858.CD006281.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1001\/archneur.60.11.1601","article-title":"A phase 1 trial of riluzole in spinal muscular atrophy","volume":"60","author":"Russman","year":"2003","journal-title":"Archives of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD006281.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.20836","article-title":"In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate","volume":"59","author":"Brichta","year":"2006","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006281.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mus.25776","article-title":"Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I","volume":"57","author":"Krosschell","year":"2018","journal-title":"Muscle & Nerve"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006281.pub5-BIB0006|cit6","first-page":"2402","article-title":"Treatment of spinal muscular atrophy by hydroxyurea","volume":"71","author":"Chang","year":"2002","journal-title":"American Journal of Human Genetics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006281.pub5-BIB0007|cit7","first-page":"63","article-title":"Analysis of motor skill acquisition among children with type I spinal muscular atrophy submitted to medication with valproic acid","volume":"11","author":"Conceicao","year":"2010","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"Suppl 20","key":"10.1002\/14651858.CD006281.pub5-BIB0008|cit8","first-page":"S371","article-title":"Interim results of a phase 2 clinical study of nusinersen (ISIS-SMNRx) in patients with infantile-onset spinal muscular atrophy","volume":"80","author":"Finkel","year":"2016","journal-title":"Annals of Neurology"},{"issue":"10063","key":"10.1002\/14651858.CD006281.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0010|cit10","unstructured":"NCT01839656 A study to assess the safety and pharmacokinetics of ionis SMNRX in infants with spinal muscular atrophy www.clinicaltrials.gov\/show\/NCT01839656"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0011|cit11","unstructured":"NCT02913482 A study to Investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type1 spinal muscular atrophy (Firefish) clinicaltrials.gov\/show\/NCT02913482"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0012|cit12","unstructured":"Franz DN Tudor CA Samaha FJ A phase I trial of recombinant human ciliary neurotrophic factor in spinal muscular atrophy Annals of Neurology 1995 546"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0013|cit13","unstructured":"JPRN-JapicCTI-163450 Phase 3 study of K-828-SP apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-JapicCTI-163450 (first received November 2016)"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006281.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S1525-0016(16)33289-0","article-title":"Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes","volume":"24","author":"Mendell","year":"2016","journal-title":"Molecular Therapy"},{"issue":"18","key":"10.1002\/14651858.CD006281.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0016|cit16","unstructured":"NCT02122952 Gene transfer clinical trial for spinal muscular atrophy type 1 www.clinicaltrial.gov\/show\/NCT0122952"},{"issue":"Suppl 20","key":"10.1002\/14651858.CD006281.pub5-BIB0017|cit17","first-page":"S368","article-title":"Interim safety, efficacy and achievement of developmental milestones in this phase 1, first-in-human study of the systemic delivery of AVXS-101, an AAV9-mediated gene therapy for children with spinal muscular atrophy (SMA) type 1","volume":"80","author":"Sproule","year":"2016","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0018|cit18","unstructured":"NCT02268552 An open label study of LMI070 in type 1 spinal muscular atrophy (SMA) www.clinicaltrials.gov\/show\/NCT02268552"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0019|cit19","unstructured":"NCT02855112 Allogeneic adipose derived stem cells for Werdnig Hoffman patients clinicaltrials.gov\/show\/NCT02855112"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0020|cit20","unstructured":"NCT02865109 To provide access to nusinersen to eligible patients with Infantile-onset Spinal Muscular Atrophy (SMA) (consistent with Type 1) to address a high-unmet medical need clinicaltrials.gov\/show\/NCT02865109"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0021|cit21","unstructured":"NCT00439218 Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy type I clinicaltrials.gov\/show\/NCT00439218"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006281.pub5-BIB0022|cit22","first-page":"S101","article-title":"Long-term open salbutamol trial in spinal muscular atrophy","volume":"257","author":"Prufer de Queiroz Campos Araujo","year":"2010","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0023|cit23","unstructured":"NCT02594124 An open-label study (SHINE) for patients with spinal muscular atrophy (sma) who participated in studies with IONIS-SMNRX clinicaltrials.gov\/show\/NCT02594124"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0024|cit24","unstructured":"SMART01 Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy dbcentre3.jmacct.med.or.jp\/JMACTR\/App\/JMACTRS06\/JMACTRS06.aspx?seqno=4602 (first received July 2014)"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"e5268","DOI":"10.1371\/journal.pone.0005268","article-title":"Phase II open label study of valproic acid in spinal muscular atrophy","volume":"4","author":"Swoboda","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/PHM.0000000000000309","article-title":"Allogeneic mesenchymal stem cell therapy outcomes for three patients with spinal muscular atrophy type 1","volume":"94","author":"Villanova","year":"2015","journal-title":"American Journal of Physical Medicine & Rehabilitation"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0027|cit27","unstructured":"MOONFISH - NCT02240355 A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH) clinicaltrials.gov\/show\/NCT02240355"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0028|cit28","unstructured":"NCT00568698 A pilot therapeutic trial using hydroxyurea in type I spinal muscular atrophy patients clinicaltrials.gov\/show\/NCT00568698"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0029|cit29","unstructured":"NCT02462759 A study to assess the safety and tolerability of ISIS 396443 (ISIS SMNRx) in participants with spinal muscular atrophy (SMA). (EMBRACE) clinicaltrials.gov\/show\/NCT02462759"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0030|cit30","unstructured":"SMART02 Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: confirmatory trial (SMART02) dbcentre3.jmacct.med.or.jp\/JMACTR\/App\/JMACTRS06\/JMACTRS06.aspx?seqno=5544 (first received January 2016)"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2125.2010.03843.x","article-title":"Riluzole pharmacokinetics in young patients with spinal muscular atrophy","volume":"71","author":"Abbara","year":"2011","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"19","key":"10.1002\/14651858.CD006281.pub5-BIB0032|cit32","first-page":"e88427","article-title":"ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice","volume":"1","author":"Abera","year":"2017","journal-title":"JCI Insight"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1212\/WNL.46.5.1244","article-title":"A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis","volume":"46","author":"ALS CNTF Treatment Study Group","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/ejhg.2011.89","article-title":"Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability","volume":"19","author":"Also-Rallo","year":"2011","journal-title":"European Journal of Human Genetics"},{"issue":"8","key":"10.1002\/14651858.CD006281.pub5-BIB0035|cit35","first-page":"895","article-title":"Advances and challenges in developing a therapy for spinal muscular atrophy","volume":"15","author":"Anderton","year":"2015","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejphar.2017.08.005","article-title":"Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model","volume":"814","author":"Ando","year":"2017","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","article-title":"Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy","volume":"12","author":"Andreassi","year":"2004","journal-title":"European Journal of Human Genetics"},{"issue":"6","key":"10.1002\/14651858.CD006281.pub5-BIB0038|cit38","first-page":"460","article-title":"Guanidine hydrochloride in infantile and juvenile spinal muscular atrophy. A double blind controlled study","volume":"2","author":"Angelini","year":"1980","journal-title":"Acta Neurologica"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1651-2227.2008.01201.x","article-title":"A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy","volume":"98","author":"Arkblad","year":"2009","journal-title":"Acta Paediatrica"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.23995","article-title":"Spinal Muscular Atrophy: the development and implementation of potential treatments running head","volume":"74","author":"Arnold","year":"2013","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0041|cit41","unstructured":"ASIRI - NCT00774423 Study to evaluate the efficacy of riluzole in children and young adults with spinal muscular atrophy (SMA) (ASIRI) www.clinicaltrials.gov\/show\/NCT00774423"},{"issue":"7454","key":"10.1002\/14651858.CD006281.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"GRADE Working Group. Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI29562","article-title":"Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy","volume":"117","author":"Avila","year":"2007","journal-title":"Journal of Clinical Investigation"},{"issue":"12","key":"10.1002\/14651858.CD006281.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1172\/JCI22922","article-title":"Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy","volume":"114","author":"Azzouz","year":"2004","journal-title":"Journal of Clinical Investigation"},{"issue":"2","key":"10.1002\/14651858.CD006281.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/mt.2012.261","article-title":"Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice","volume":"21","author":"Benkhelifa-Ziyyat","year":"2013","journal-title":"Molecular Therapy"},{"issue":"17","key":"10.1002\/14651858.CD006281.pub5-BIB0046|cit46","first-page":"30085","article-title":"Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"S1474-4422","author":"Bertini","year":"2017","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00415-013-7154-1","article-title":"Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe","volume":"261","author":"Bladen","year":"2014","journal-title":"Jounal of Neurology"},{"issue":"43","key":"10.1002\/14651858.CD006281.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"E5863","DOI":"10.1073\/pnas.1509758112","article-title":"Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II\/III spinal muscular atrophy","volume":"112","author":"Bogdanik","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of United States of America"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004302.pub2","article-title":"Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis\/motor neuron disease","author":"Bongioanni","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD006281.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddq021","article-title":"Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model","volume":"19","author":"Bowerman","year":"2010","journal-title":"Human Molecular Genetics"},{"issue":"10","key":"10.1002\/14651858.CD006281.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1741-7015-10-24","article-title":"Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy","volume":"7","author":"Bowerman","year":"2012","journal-title":"BMC Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006281.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.ejhg.5201320","article-title":"Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients","volume":"13","author":"Brahe","year":"2005","journal-title":"European Journal of Human Genetics"},{"issue":"8951","key":"10.1002\/14651858.CD006281.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0140-6736(95)90869-2","article-title":"Constitutive muscular abnormalities in culture in spinal muscular atrophy","volume":"345","author":"Braun","year":"1995","journal-title":"Lancet"},{"issue":"19","key":"10.1002\/14651858.CD006281.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Human Molecular Genetics"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-199652040-00010","article-title":"Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis","volume":"52","author":"Bryson","year":"1996","journal-title":"Drugs"},{"issue":"6266","key":"10.1002\/14651858.CD006281.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/344540a0","article-title":"Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3","volume":"344","author":"Brzustowicz","year":"1990","journal-title":"Nature"},{"issue":"8","key":"10.1002\/14651858.CD006281.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nature Reviews Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/hmg\/ddp510","article-title":"Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy","volume":"19","author":"Butchbach","year":"2010","journal-title":"Human Molecular Genetics"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.expneurol.2016.02.009","article-title":"Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy","volume":"279","author":"Butchbach","year":"2016","journal-title":"Experimental Neurology"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.biopha.2017.01.104","article-title":"Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells","volume":"88","author":"Chen","year":"2017","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"9","key":"10.1002\/14651858.CD006281.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"eCollection 201","DOI":"10.1371\/journal.pone.0185079","article-title":"In vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: Context-specific modulation of SMN transcript levels","volume":"12","author":"Cherry","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1002\/14651858.CD006281.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/spen.2002.33801","article-title":"Spinal muscular atrophy","volume":"9","author":"Cifuentes-Diaz","year":"2002","journal-title":"Seminars in Pediatric Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0063|cit63","first-page":"805","article-title":"Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy","volume":"57","author":"Cobben","year":"1995","journal-title":"American Journal of Human Genetics"},{"issue":"52","key":"10.1002\/14651858.CD006281.pub5-BIB0064|cit64","first-page":"2525","article-title":"From gene to disease; 'survival' motor neuron protein and hereditary proximal spinal muscle atrophy","volume":"145","author":"Cobben","year":"2001","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"issue":"7","key":"10.1002\/14651858.CD006281.pub5-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.nmd.2008.05.008","article-title":"Survival in SMA type I: a prospective analysis of 34 consecutive cases","volume":"18","author":"Cobben","year":"2008","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0066|cit66","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2016.11.033","article-title":"The antisense transcript SMN-AS1 regulates SMN expression and Is a novel therapeutic target for spinal muscular atrophy","volume":"93","author":"d'Ydewalle","year":"2017","journal-title":"Neuron"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2377-11-36","article-title":"Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid","volume":"11","author":"Darbar","year":"2011","journal-title":"BMC Neurology"},{"issue":"6","key":"10.1002\/14651858.CD006281.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/MOP.0b013e3282f1884c","article-title":"Clinical trials in spinal muscular atrophy","volume":"19","author":"Darras","year":"2007","journal-title":"Current Opinion in Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/hmg\/ddq514","article-title":"Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice","volume":"20","author":"Dominguez","year":"2011","journal-title":"Human Molecular Genetics"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1517\/14712598.2012.711306","article-title":"Update on gene and stem cell therapy approaches for spinal muscular atrophy","volume":"11","author":"Donnelly","year":"2012","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0960-8966(94)00075-K","article-title":"Chaos in the classification of SMA: a possible resolution","volume":"5","author":"Dubowitz","year":"1995","journal-title":"Neuromuscular Disorders"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.24332","article-title":"A large animal model of spinal muscular atrophy and correction of phenotype","volume":"77","author":"Duque","year":"2015","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3233\/JND-160187","article-title":"Effect of the butyrate prodrug pivaloyloxymethyl butyrate (AN9) on a mouse model for spinal muscular atrophy","volume":"3","author":"Edwards","journal-title":"Journal of Neuromuscular Disorders"},{"issue":"2","key":"10.1002\/14651858.CD006281.pub5-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"American Journal of Human Genetics"},{"issue":"9","key":"10.1002\/14651858.CD006281.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006281.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7-9 November 2014, Heemskerk, The Netherlands","volume":"25","author":"Finkel","year":"2015","journal-title":"Neuromuscular Disorders"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromusculular Disordorders"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0925-4439(95)00040-B","article-title":"Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies","volume":"1271","author":"Folkers","year":"1995","journal-title":"Biochimica et Biophysica Acta"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nature Biotechnology"},{"issue":"19","key":"10.1002\/14651858.CD006281.pub5-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1093\/hmg\/ddp313","article-title":"LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate","volume":"18","author":"Garbes","year":"2009","journal-title":"Human Molecular Genetics"},{"issue":"8","key":"10.1002\/14651858.CD006281.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/hmg\/ddm379","article-title":"Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect","volume":"17","author":"Gavrilina","year":"2008","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10.1002\/14651858.CD006281.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00019052-199904000-00002","article-title":"Spinal muscular atrophy: molecular pathophysiology","volume":"12","author":"Gendron","year":"1999","journal-title":"Current Opinion in Neurology"},{"issue":"6278","key":"10.1002\/14651858.CD006281.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/345823a0","article-title":"Genetic homogeneity between acute and chronic forms of spinal muscular atrophy","volume":"345","author":"Gilliam","year":"1990","journal-title":"Nature"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bbrc.2011.11.121","article-title":"Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy","volume":"417","author":"Glascock","year":"2012","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/hum.2011.166","article-title":"Decreasing disease severity in symptomatic, SMN(-\/-);SMN2(+\/+), spinal muscular atrophy mice following scAAV9-SMN delivery","volume":"23","author":"Glascock","year":"2012","journal-title":"Human Gene Therapy"},{"issue":"20","key":"10.1002\/14651858.CD006281.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1093\/hmg\/ddt258","article-title":"The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models","volume":"22","author":"Gogliotti","year":"2013","journal-title":"Human Molecular Genetics"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0088|cit88","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT"},{"issue":"24","key":"10.1002\/14651858.CD006281.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1212\/WNL.0b013e3182020332","article-title":"Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy","volume":"75","author":"Chen","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/mus.10455","article-title":"Riluzole attenuates spinal muscular atrophy disease progression in a mouse model","volume":"28","author":"Haddad","year":"2003","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1750-1172-9-4","article-title":"VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models","volume":"9","author":"Hadwen","year":"2014","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1471-4159.2006.03868.x","article-title":"In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy","volume":"98","author":"Hahnen","year":"2006","journal-title":"Journal Neurochemistry"},{"issue":"39","key":"10.1002\/14651858.CD006281.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proceedings of the National Academy of Sciences in the United States of America"},{"issue":"9","key":"10.1002\/14651858.CD006281.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00415-002-0811-4","article-title":"Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity","volume":"249","author":"Harada","year":"2002","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"5ra12","DOI":"10.1126\/scitranslmed.3000208","article-title":"Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy","volume":"1","author":"Hastings","year":"2009","journal-title":"Science Translational Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006281.pub5-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/hmg\/ddn357","article-title":"Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition","volume":"18","author":"Hauke","year":"2009","journal-title":"Human Molecular Genetics"},{"issue":"7","key":"10.1002\/14651858.CD006281.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/hmg\/ddp030","article-title":"Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo","volume":"18","author":"Heier","year":"2009","journal-title":"Human Molecular Genetics"},{"issue":"7","key":"10.1002\/14651858.CD006281.pub5-BIB0098|cit98","first-page":"107","article-title":"ECG in neonate mice with spinal muscular atrophy allows assessment of drug efficacy","volume":"1","author":"Heier","year":"2015","journal-title":"Frontiers in Bioscience (Elite Edition)"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0099|cit99","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajhg.2016.07.014","article-title":"The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype","volume":"99","author":"Hosseinibarkooie","year":"2016","journal-title":"American Journal of Human Genetics"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1476-5381.2012.01829.x","article-title":"Triptolide increases transcript and protein levels of survival motor neurons in human SMA fibroblasts and improves survival in SMA-like mice","volume":"166","author":"Hsu","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"15","key":"10.1002\/14651858.CD006281.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes & Development"},{"issue":"7367","key":"10.1002\/14651858.CD006281.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0887-8994(93)90082-N","article-title":"Prospective study of spinal muscular atrophy before age 6 years. DCN\/SMA Group","volume":"9","author":"Iannaccone","year":"1993","journal-title":"Pediatric Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-2008-1040858","article-title":"Spinal muscular atrophy","volume":"18","author":"Iannaccone","year":"1998","journal-title":"Seminars in Neurology"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0106|cit106","first-page":"83","article-title":"Spinal muscular atrophies","volume-title":"Neuromuscular Disorders","author":"Iannaccone","year":"2001"},{"issue":"11","key":"10.1002\/14651858.CD006281.pub5-BIB0107|cit107","first-page":"1657","article-title":"Use of lithium carbonate to treat Kugelberg-Welander spinal amyotrophy","volume":"80","author":"Il'ina","year":"1980","journal-title":"Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006281.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"I37","DOI":"10.1007\/s004150050555","article-title":"The role of SMN in spinal muscular atrophy","volume":"247","author":"Jablonka","year":"2000","journal-title":"Journal of Neurology"},{"issue":"14","key":"10.1002\/14651858.CD006281.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1093\/hmg\/ddi205","article-title":"Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy","volume":"14","author":"Jarecki","year":"2005","journal-title":"Human Molecular Genetics"},{"issue":"7","key":"10.1002\/14651858.CD006281.pub5-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1517\/13543784.2015.1038341","article-title":"Investigational therapies for the treatment of spinal muscular atrophy","volume":"24","author":"Kaczmarek","year":"2015","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"16","key":"10.1002\/14651858.CD006281.pub5-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","article-title":"Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy","volume":"17","author":"Kariya","year":"2008","journal-title":"Human Molecular Genetics"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1038\/mtna.2014.23","article-title":"A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy","volume":"3","author":"Keil","year":"2014","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"9","key":"10.1002\/14651858.CD006281.pub5-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","article-title":"The role of histone acetylation in SMN gene expression","volume":"14","author":"Kernochan","year":"2005","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neuroscience.2007.04.018","article-title":"Anti-glutamatergic effect of riluzole: comparison with valproic acid","volume":"147","author":"Kim","year":"2007","journal-title":"Neuroscience"},{"issue":"7","key":"10.1002\/14651858.CD006281.pub5-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"e21296","DOI":"10.1371\/journal.pone.0021296","article-title":"SMA carni-val trial part II: a prospective, single- armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy","volume":"6","author":"Kissel","year":"2011","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1053\/ejpn.2001.0510","article-title":"Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III","volume":"5","author":"Kroksmark","year":"2001","journal-title":"European Journal of Paediatric Neurology"},{"issue":"18","key":"10.1002\/14651858.CD006281.pub5-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1093\/hmg\/ddr288","article-title":"Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice","volume":"20","author":"Kwon","year":"2011","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"10","key":"10.1002\/14651858.CD006281.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/hmg\/7.10.1531","article-title":"The role of the SMN gene in proximal spinal muscular atrophy","volume":"7","author":"Lefebvre","year":"1998","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11910-011-0240-9","article-title":"New therapeutic approaches to spinal muscular atrophy","volume":"12","author":"Lewelt","year":"2012","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"1-2","key":"10.1002\/14651858.CD006281.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jns.2007.11.012","article-title":"The effect of hydroxyurea in spinal muscular atrophy cells and patients","volume":"268","author":"Liang","year":"2008","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1002\/14651858.CD006281.pub5-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/mt.2014.209","article-title":"PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy","volume":"23","author":"Little","year":"2015","journal-title":"Molecular Therapy"},{"issue":"7","key":"10.1002\/14651858.CD006281.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"e101225","DOI":"10.1371\/journal.pone.0101225","article-title":"The sm-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1002\/14651858.CD006281.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"e0166803","DOI":"10.1371\/journal.pone.0166803","article-title":"Activin receptor type IIB inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1002\/14651858.CD006281.pub5-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"e0166803","DOI":"10.1371\/journal.pone.0166803","article-title":"Activin receptor type IIB inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1002\/14651858.CD006281.pub5-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.chembiol.2004.08.024","article-title":"Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism","volume":"11","author":"Lunn","year":"2004","journal-title":"Chemistry & Biology"},{"issue":"9630","key":"10.1002\/14651858.CD006281.pub5-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD006281.pub5-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/hmg\/ddp333","article-title":"Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model","volume":"18","author":"Mattis","year":"2009","journal-title":"Human Molecular Genetics"},{"issue":"10","key":"10.1002\/14651858.CD006281.pub5-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1471-2202-10-142","article-title":"Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA","volume":"30","author":"Mattis","year":"2009","journal-title":"BMC Neuroscience"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neulet.2012.07.024","article-title":"Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy","volume":"525","author":"Mattis","year":"2012","journal-title":"Neuroscience Letters"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1083\/jcb.200303168","article-title":"Knockdown of the survival motor neuron (smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding","volume":"162","author":"McWhorter","year":"2003","journal-title":"The Journal of Cell Biology"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0133|cit133","volume-title":"Methodological Expectations of Cochrane Intervention Reviews","volume":"1.02","author":"Higgins","year":"2018"},{"issue":"6268","key":"10.1002\/14651858.CD006281.pub5-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/344767a0","article-title":"Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q","volume":"344","author":"Melki","year":"1990","journal-title":"Nature"},{"issue":"8710","key":"10.1002\/14651858.CD006281.pub5-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0140-6736(90)91803-I","article-title":"Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. The French Spinal Muscular Atrophy Investigators","volume":"336","author":"Melki","year":"1990","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006281.pub5-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S1525-0016(16)33289-0","article-title":"Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes","volume":"24","author":"Mendell","year":"2016","journal-title":"Molecular Therapy"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006281.pub5-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscular Disorders"},{"issue":"8","key":"10.1002\/14651858.CD006281.pub5-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/08830738030180080501","article-title":"Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study","volume":"18","author":"Merlini","year":"2003","journal-title":"Journal of Child Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Molecular Therapy"},{"issue":"2","key":"10.1002\/14651858.CD006281.pub5-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.410390215","article-title":"A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group","volume":"39","author":"Miller","year":"1996","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006281.pub5-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1590\/S1415-47572013000300001","article-title":"Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy","volume":"36","author":"Mohseni","year":"2013","journal-title":"Genetics and Molecular Biololgy"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/jhg.2016.61","article-title":"Transcript, methylation and molecular docking analyses of the effects of HDAC inhibitors, SAHA and Dacinostat, on SMN2 expression in fibroblasts of SMA patients","volume":"61","author":"Mohseni","year":"2016","journal-title":"Journal of Human Genetics"},{"issue":"5-6","key":"10.1002\/14651858.CD006281.pub5-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting (26-28 June 1992, Bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscular Disorders"},{"issue":"7","key":"10.1002\/14651858.CD006281.pub5-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/hmg\/ddm367","article-title":"Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy","volume":"17","author":"Murray","year":"2008","journal-title":"Human Molecular Genetics"},{"issue":"6197","key":"10.1002\/14651858.CD006281.pub5-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0148|cit148","unstructured":"NCT02628743 A study to evaluate long term safety, tolerability, and effectiveness of olesoxime in patients with spinal muscular atrophy clinicaltrials.gov\/show\/NCT02628743"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mus.10110","article-title":"Spinal muscular atrophy: recent advances and future prospects","volume":"26","author":"Nicole","year":"2002","journal-title":"Muscle & Nerve"},{"issue":"16","key":"10.1002\/14651858.CD006281.pub5-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/hmg\/ddq226","article-title":"PTEN depletion rescues axonal growth defect and improves survival in SMN-deficient motor neurons","volume":"19","author":"Ning","year":"2010","journal-title":"Human Molecular Genetics"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.clinthera.2014.02.004","article-title":"Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy \u03947 mouse model phenotype","volume":"36","author":"Nizzardo","year":"2014","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ahg.12031","article-title":"Spinal muscular atrophy: from gene discovery to clinical trials","volume":"77","author":"Nurputra","year":"2013","journal-title":"Annals of Human Genetics"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0153|cit153","unstructured":"NCT02386553 A study of multiple doses of ionis smnrx (ISIS 396443) delivered to infants with genetically diagnosed and presymptomatic spinal muscular atrophy (NURTURE) www.clinicaltrials.gov\/show\/NCT02386553"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000290830.40544.b9","article-title":"The changing natural history of spinal muscular atrophy type I","volume":"69","author":"Oskoui","year":"2007","journal-title":"Neurology"},{"issue":"18","key":"10.1002\/14651858.CD006281.pub5-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/hmg\/ddu198","article-title":"Morpholino antisense oligonucleotides targeting intronic repressor element 1 improve phenotype in SMA mouse models","volume":"23","author":"Osman","year":"2015","journal-title":"Human Molecular Genetics"},{"issue":"9","key":"10.1002\/14651858.CD006281.pub5-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/mt.2016.145","article-title":"Optimization of morpholino antisense oligonucleotides targeting the intronic repressor element1 in spinal muscular atrophy","volume":"24","author":"Osman","year":"2016","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF03033366","article-title":"Survival motor neuron protein regulates apoptosis in an in vitro model of spinal muscular atrophy","volume":"13","author":"Parker","year":"2008","journal-title":"Neurotoxicity Research"},{"issue":"72","key":"10.1002\/14651858.CD006281.pub5-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Science Translational Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0092-8674(00)81632-3","article-title":"A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing","volume":"95","author":"Pellizzoni","year":"1998","journal-title":"Cell"},{"issue":"9","key":"10.1002\/14651858.CD006281.pub5-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00415-008-0929-0","article-title":"A natural history study of late onset spinal muscular atrophy types 3b and 4","volume":"255","author":"Piepers","year":"2008","journal-title":"Journal of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD006281.pub5-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.2009.200253","article-title":"Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid","volume":"82","author":"Piepers","year":"2011","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/hum.2012.225","article-title":"Antisense oligonucleotides for the treatment of spinal muscular atrophy","volume":"24","author":"Porensky","year":"2013","journal-title":"Human Gene Therapy"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0163|cit163","unstructured":"NCT03779334 A study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (Rainbowfish) www.clinicaltrial.gov"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0164|cit164","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00439-006-0186-1","article-title":"The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA\/protein levels in spinal muscular atrophy cells","volume":"120","author":"Riessland","year":"2006","journal-title":"Human Genetics"},{"issue":"8","key":"10.1002\/14651858.CD006281.pub5-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","article-title":"SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy","volume":"19","author":"Riessland","year":"2010","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10.1002\/14651858.CD006281.pub5-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","article-title":"Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis","volume":"100","author":"Riessland","year":"2017","journal-title":"American Journal of Human Genetics"},{"issue":"17","key":"10.1002\/14651858.CD006281.pub5-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1093\/hmg\/ddu169","article-title":"Defining the therapeutic window in a severe animal model of spinal muscular atrophy","volume":"23","author":"Robbins","year":"2014","journal-title":"Human Molecular Genetics"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1083\/jcb.200304128","article-title":"Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons","volume":"163","author":"Rossoll","year":"2003","journal-title":"Journal of Cell Biology"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/088307389200700403","article-title":"Spinal muscular atrophy: new thoughts on the pathogenesis and classification schema","volume":"7","author":"Russman","year":"1992","journal-title":"Journal of Child Neurology"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ncn3.140","article-title":"A study of valproic acid for patients with spinal muscular atrophy","volume":"3","author":"Saito","year":"2015","journal-title":"Neurology and Clinical Neuroscience"},{"issue":"6","key":"10.1002\/14651858.CD006281.pub5-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ejhg.2012.222","article-title":"Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585","volume":"21","author":"Schreml","year":"2013","journal-title":"European Journal of Human Genetics"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0173|cit173","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0174|cit174","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"12","key":"10.1002\/14651858.CD006281.pub5-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.bbadis.2013.08.005","article-title":"Spinal muscular atrophy: an update on therapeutic progress","volume":"1832","author":"Seo","year":"2013","journal-title":"Biochimica Biophysica Acta"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s12031-011-9614-3","article-title":"Optimization of SMN trans-splicing through the analysis of SMN introns","volume":"46","author":"Shababi","year":"2012","journal-title":"Journal Molecular Neuroscience"},{"issue":"11","key":"10.1002\/14651858.CD006281.pub5-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1021\/cb800120t","article-title":"DcpS as a therapeutic target for spinal muscular atrophy","volume":"3","author":"Singh","year":"2008","journal-title":"ACS Chemical Biology"},{"issue":"7","key":"10.1002\/14651858.CD006281.pub5-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1073\/pnas.0633863100","article-title":"Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts","volume":"100","author":"Skordis","year":"April 2003","journal-title":"Proceedings of National Acadamy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0179|cit179","unstructured":"SPACE SPACE trial SMA and Pyridostigmine in Adults and Children; Experimental trial to assess effect of pyridostigmine compared to placebo in patients with spinal muscular atrophy types 2, 3 and 4 apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-004369-34-NL"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ygeno.2015.01.007","article-title":"Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7","volume":"105","author":"Staropoli","year":"2015","journal-title":"Genomics"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0181|cit181","first-page":"3","article-title":"Spinal muscular atrophy disease: a literature review for therapeutic strategies","volume":"3","author":"Stavarachi","year":"January-March 2010","journal-title":"Journal of Medicine and Life"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0182|cit182","unstructured":"STOPSMA - NCT00528268 Study to evaluate sodium phenylbutyrate in pre-symptomatic infants with spinal muscular atrophy (STOPSMA) www.clinicaltrials.gov\/show\/NCT00528268"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD006281.pub5-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0883073807305787","article-title":"Molecular mechanisms of spinal muscular atrophy","volume":"22","author":"Sumner","year":"2007","journal-title":"Journal of Child Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD006281.pub5-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0883073807305665","article-title":"Perspectives on clinical trials in spinal muscular atrophy","volume":"22","author":"Swoboda","year":"2007","journal-title":"Journal of Child Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1023\/A:1005516625866","article-title":"Spinal muscular atrophy","volume":"22","author":"Talbot","year":"1999","journal-title":"Journal of Inherited Metabolic Diseases"},{"issue":"5-6","key":"10.1002\/14651858.CD006281.pub5-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0960-8966(94)90090-6","article-title":"The natural history of type I (severe) spinal muscular atrophy","volume":"4","author":"Thomas","year":"1994","journal-title":"Neuromuscular Disorders"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/jm061475p","article-title":"Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy","volume":"51","author":"Thurmond","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"10.1002\/14651858.CD006281.pub5-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/hmg\/ddl482","article-title":"Stat5 constitutive activation rescues defects in spinal muscular atrophy","volume":"16","author":"Ting","year":"2007","journal-title":"Human Molecular Genetics"},{"issue":"23","key":"10.1002\/14651858.CD006281.pub5-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1523\/JNEUROSCI.0417-15.2015","article-title":"Disease mechanisms and therapeutic approaches in spinal muscular atrophy","volume":"35","author":"Tisdale","year":"2015","journal-title":"Journal of Neuroscience"},{"issue":"12","key":"10.1002\/14651858.CD006281.pub5-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/j.1468-1331.2007.01992.x","article-title":"Valproic acid treatment in six patients with spinal muscular atrophy","volume":"14","author":"Tsai","year":"2007","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.phrs.2016.05.023","article-title":"Loganin possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt\/mTOR in experimental models of spinal muscular atrophy","volume":"111","author":"Tseng","year":"2016","journal-title":"Pharmacological Research"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cbin.10395","article-title":"Effects of flavonoid quercetin on survival of motor neuron gene expression","volume":"39","author":"Uzunall\u0131","year":"2015","journal-title":"Cell Biology International"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0195|cit195","first-page":"35","article-title":"Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy","volume":"35","author":"Valori","year":"2010","journal-title":"Science Translational Medicine"},{"issue":"20","key":"10.1002\/14651858.CD006281.pub5-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1093\/hmg\/ddt257","article-title":"The DcpS inhibitor RG3039 improves motor function in SMA mice","volume":"22","author":"Meerbeke","year":"2013","journal-title":"Human Molecular Genetics"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","article-title":"Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0-4","volume":"88","author":"Wadman","year":"2017","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD006281.pub5-BIB0198|cit198","unstructured":"Wadman RI van der Pol WL Bosboom WMJ van den Berg LH Iannaccone ST Vrancken AFJE Drug treatment for spinal muscular atrophy types II and III Cochrane Database of Systematic Reviews 10.1002\/14651858.CD006282.pub5"},{"issue":"8","key":"10.1002\/14651858.CD006281.pub5-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"Journal of Child Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/01.wnl.0000231139.26253.d0","article-title":"Valproate may improve strength and function in patients with type III\/IV spinal muscle atrophy","volume":"67","author":"Weihl","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006281.pub5-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.spen.2006.06.008","article-title":"Spinal muscular atrophy: from gene to therapy","volume":"13","author":"Wirth","year":"2006","journal-title":"Seminars in Pediatric Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI71318","article-title":"Dysregulation of ubiquitin homeostasis and \u03b2-catenin signaling promote spinal muscular atrophy","volume":"124","author":"Wishart","year":"2014","journal-title":"Journal of Clinical Investigation"},{"issue":"13","key":"10.1002\/14651858.CD006281.pub5-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1021\/acs.jmedchem.6b00460","article-title":"Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy","volume":"59","author":"Woll","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"9","key":"10.1002\/14651858.CD006281.pub5-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/hmg\/ddi131","article-title":"A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels","volume":"14","author":"Wolstencroft","year":"2005","journal-title":"Human Molecular Genetics"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CND.0b013e3180315c99","article-title":"A randomized, placebo-controlled trial of creatine in children with spinal muscular atrophy","volume":"8","author":"Wong","year":"2007","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"8","key":"10.1002\/14651858.CD006281.pub5-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"E1509","DOI":"10.1073\/pnas.1616521114","article-title":"Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy","volume":"114","author":"Woo","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ana.21241","article-title":"5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells","volume":"63","author":"Yuo","year":"2008","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.clinthera.2013.11.006","article-title":"Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials","volume":"36","author":"Zanetta","year":"2014","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0960-8966(99)00016-4","article-title":"59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria 17-19 April 1998, Soestduinen, The Netherlands","volume":"9","author":"Zerres","year":"1999","journal-title":"Neuromuscular Disorders"},{"issue":"20","key":"10.1002\/14651858.CD006281.pub5-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/sj.gt.3301550","article-title":"An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA","volume":"8","author":"Zhang","year":"2001","journal-title":"Gene Therapy"},{"issue":"3","key":"10.1002\/14651858.CD006281.pub5-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/hum.2012.211","article-title":"A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice","volume":"24","author":"Zhou","year":"2013","journal-title":"Human Gene Therapy"},{"issue":"22","key":"10.1002\/14651858.CD006281.pub5-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1093\/hmg\/ddv329","article-title":"Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response","volume":"24","author":"Zhou","year":"2015","journal-title":"Human Molecular Genetics"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.bbrc.2007.10.096","article-title":"SMN protects cells against mutant SOD1 toxicity by increasing chaperone activity","volume":"364","author":"Zou","year":"2007","journal-title":"Biochemical and Biophysical Research Communication"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0214|cit214","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006281","article-title":"Drug treatment for spinal muscular atrophy type I","author":"Bosboom","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006281.pub5-BIB0215|cit215","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006281.pub2","article-title":"Drug treatment for spinal muscular atrophy type I","author":"Bosboom","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006281.pub5-BIB0216|cit216","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006281.pub3","article-title":"Drug treatment for spinal muscular atrophy type I","author":"Wadman","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006281.pub5\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:57:23Z","timestamp":1628546243000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006281.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,11]]},"references-count":216,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006281.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,11]]}}}